Free Trial
→ Elon just declared war on your phone (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$60.77
-0.7%		$73.88
$1.16
▼
$14.10
$2.63B-0.12189,291 shs846,822 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$21.58
+1.5%		$24.91
$20.91
▼
$42.21
$2.54B0.11.79 million shs1.27 million shs
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
$21.12
+4.9%		$21.83
$5.55
▼
$29.27
$657.12M-0.24217,725 shs152,960 shs
Precigen, Inc. stock logo
PGEN
Precigen
$7.81
+2.8%		$7.25
$2.99
▼
$8.98
$2.71B0.925.69 million shs3.38 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-0.67%-4.46%-20.91%-20.66%-10.49%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
+1.51%-6.98%-5.31%-38.80%-34.33%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
+4.92%-3.65%-7.29%+15.10%+239.00%
Precigen, Inc. stock logo
PGEN
Precigen
+2.76%-8.55%+14.85%+46.80%+142.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$60.77
-0.7%		$73.88
$1.16
▼
$14.10
$2.63B-0.12189,291 shs846,822 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$21.58
+1.5%		$24.91
$20.91
▼
$42.21
$2.54B0.11.79 million shs1.27 million shs
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
$21.12
+4.9%		$21.83
$5.55
▼
$29.27
$657.12M-0.24217,725 shs152,960 shs
Precigen, Inc. stock logo
PGEN
Precigen
$7.81
+2.8%		$7.25
$2.99
▼
$8.98
$2.71B0.925.69 million shs3.38 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-0.67%-4.46%-20.91%-20.66%-10.49%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
+1.51%-6.98%-5.31%-38.80%-34.33%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
+4.92%-3.65%-7.29%+15.10%+239.00%
Precigen, Inc. stock logo
PGEN
Precigen
+2.76%-8.55%+14.85%+46.80%+142.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.85
Moderate Buy$49.00127.06% Upside
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
2.80
Moderate Buy$36.2571.64% Upside
Precigen, Inc. stock logo
PGEN
Precigen
2.50
Moderate Buy$13.6774.99% Upside

Current Analyst Ratings Breakdown

Latest NVCT, PGEN, GMTX, and NAMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/5/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$50.00 ➝ $42.00
10/5/2026
Precigen, Inc. stock logo
PGEN
Precigen
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/25/2026
Precigen, Inc. stock logo
PGEN
Precigen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
9/24/2026
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$39.00
9/24/2026
Precigen, Inc. stock logo
PGEN
Precigen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
9/21/2026
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/8/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$52.00
9/4/2026
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/1/2026
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
Loop Capital logo
Loop Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$40.00
9/1/2026
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
Lucid Cap Mkts logo
Lucid Cap Mkts
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/24/2026
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$7.12M362.25N/AN/A$5.97 per share3.61
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/A$0.72 per shareN/A
Precigen, Inc. stock logo
PGEN
Precigen
$85.72M32.48N/AN/A$0.06 per share130.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$2.16N/AN/AN/A-3,644.21%-34.81%-31.50%11/4/2026 (Estimated)
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$26.44M-$1.31N/AN/AN/AN/A-184.25%-105.24%11/3/2026 (Estimated)
Precigen, Inc. stock logo
PGEN
Precigen
-$250.64M-$1.04N/A10.70N/A-183.98%423.75%84.39%11/12/2026 (Estimated)

Latest NVCT, PGEN, GMTX, and NAMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.50N/AN/AN/A$7.54 millionN/A
11/3/2026Q3 2026
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$0.22N/AN/AN/AN/AN/A
8/5/2026Q2 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4819-$0.52-$0.0381-$0.52$2.83 million$3.70 million
8/4/2026Q2 2026
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$0.2620-$0.30-$0.0380-$0.30N/AN/A
8/4/2026Q2 2026
Precigen, Inc. stock logo
PGEN
Precigen
-$0.0121$0.05+$0.0621$0.05$27.98 million$54.98 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
9.03
9.03
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/A
1.68
1.68
Precigen, Inc. stock logo
PGEN
Precigen
2.15
4.58
3.89

Institutional Ownership

CompanyInstitutional Ownership
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
96.77%
Precigen, Inc. stock logo
PGEN
Precigen
33.51%

Insider Ownership

CompanyInsider Ownership
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
28.55%
Precigen, Inc. stock logo
PGEN
Precigen
41.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
100119.54 million104.31 millionOptionable
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
1332.64 million23.32 millionNot Optionable
Precigen, Inc. stock logo
PGEN
Precigen
47356.51 million208.92 millionOptionable

Recent News About These Companies

Zacks Research Downgrades Precigen (NASDAQ:PGEN) to Hold
October 7 at 7:37 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31096036
Precigen (NASDAQ:PGEN) Downgraded by Zacks Research to Hold
October 7 at 7:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-precigen-nasdaq-pgen-downgraded-by-zacks-research-to-hold-2026-10-07/
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
October 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3000302/pgen-stock-up-more-than-50-in-3-months-here-s-what-you-should-know?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-3000302
Precigen (NASDAQ:PGEN) Stock Falls 6.5% - Here's Why
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31088118
Precigen (NASDAQ:PGEN) Stock Falls 6.5% - What's Next?
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-stock-falls-65-whats-next-2026-10-05/
PTC Therapeutics (NASDAQ:PTCT) versus Precigen (NASDAQ:PGEN) Head to Head Contrast
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086638
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
October 2, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2999327/4-low-beta-healthcare-stocks-to-buy-amid-fears-of-another-rate-hike?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2999327
Precigen (NASDAQ:PGEN) Reaches New 52-Week High - Should You Buy?
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078658
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
October 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998591/precigen-pgen-soars-6-3-is-further-upside-left-in-the-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|daily_price_change_5%-2998591
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
September 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998371/pgen-vs-irwd-which-biotech-stock-offers-better-growth-potential?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-2998371
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pgen-vs-irwd-biotech-stock-150800736.html
Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951004-precigen-the-fdas-platform-technology-designation-and-the-institutional-crossover-effect
Precigen (NASDAQ:PGEN) Hits New 12-Month High - Here's What Happened
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-hits-new-12-month-high-heres-what-happened-2026-09-30/
Head to Head Contrast: Emergent Biosolutions (NYSE:EBS) vs. Precigen (NASDAQ:PGEN)
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068357
Critical Review: TScan Therapeutics (NASDAQ:TCRX) vs. Precigen (NASDAQ:PGEN)
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063385
Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/precigen-pgen-gets-fda-recognition-015839357.html
Bank of America Corp DE Buys 1,848,414 Shares of Precigen, Inc. $PGEN
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-1848414-shares-of-precigen-inc-pgen-2026-09-27/
Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/precigen-pgen-gains-fda-platform-170940636.html
B Riley Securities initiates coverage of Precigen at buy
September 26, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/b-riley-securities-initiates-coverage-of-precigen-at-buy/ar-AA2cZ9VI
B. Riley Financial Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy"
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-b-riley-financial-upgrades-precigen-nasdaq-pgen-to-strong-buy-2026-09-26/
Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/precigen-pgen-secures-fda-platform-161139077.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$60.77 -0.41 (-0.67%)
As of 10/8/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$21.58 +0.32 (+1.51%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$21.58 0.00 (0.00%)
As of 10/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Nuvectis Pharma stock logo

Nuvectis Pharma NASDAQ:NVCT

$21.12 +0.99 (+4.92%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$21.12 0.00 (0.00%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Precigen stock logo

Precigen NASDAQ:PGEN

$7.81 +0.21 (+2.76%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$7.80 -0.01 (-0.13%)
As of 10/9/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas